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Abstract 10 
Large animal models have been widely used to facilitate the translation of 11 
Mesenchymal stem cells (MSC) from the laboratory to patient.  MSC, with their multi-12 
potent capacity, have been proposed to have therapeutic benefits in a number of 13 
pathological conditions.  Laboratory studies allow the investigation of cellular and 14 
molecular interactions, while small animal models allow initial ‘proof of concept’ 15 
experiments.  Large animals (dogs, pigs, sheep, goats, and horses) are more similar 16 
physiologically and structurally to man. These models have allowed clinically 17 
relevant assessments of safety, efficacy and dosing of different MSC sources prior to 18 
clinical trials.  In this review, we recapitulate the use of large animal models to 19 
facilitate the use of MSC to treat myocardial infarction- an example of one large 20 
animal model being considered the ‘gold standard’ for research and osteoarthritis - 21 
an example of the complexities of using different large animal models in a 22 
multifactorial disease. These examples show how large animals can provide a 23 
research platform that can be used to evaluate the value of cell based therapies and 24 
facilitate the process of ‘bench to bedside’. 25 
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Introduction  2 
Animals are used in research where there is a need to study the effect of a treatment 3 
on a whole tissue or living organism (Barré-Sinoussi and Montagutelli, 2015). 4 
Humans and animals share many similarities both morphologically and pathologically 5 
and animas are regularly used to study disease onset, progression and treatment 6 
(Solinas et al., 2014). In the development of novel therapeutics, animal models can 7 
also provide vital information on safety and efficacy prior to human studies (Bianco et 8 
al., 2013).  All animal research is tightly regulated by the country in which it is being 9 
undertaken and research on animals within the EU is regulated under Directive 10 
2010/63/EU (Macrì et al., 2013). This directive was established in all EU states in 11 
2013 to ensure a harmoniously high standard of animal research (Macrì et al., 2013). 12 
The directive ensures a contentious effort to implement strategies to reduce the 13 
number of animals used in research while refining techniques to reduce predicted 14 
pain, suffering, distress and/or lasting pain whilst also improving animal husbandry. 15 
Animal experiments are conducted on a wide variety of species including 16 
invertebrates, fish, birds and mammals (with mammalian species being divided into 17 
‘small’ animal or ‘large’ animal models). 18 
An animal is considered a ‘large animal’ when the species in question is; non rodent, 19 
rabbit or guinea pig (Thomas, Bhat and Mapara, 2012).  The more commonly used 20 
large animal models in research include horses, cows, pigs, sheep, goats, primates 21 
and dogs, and the choice of animal model depends on multiple factors, including the 22 
type of experiment, its duration, husbandry costs, handling logistics and 23 
measurement parameters (Kuyinu et al., 2016).  24 
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Whilst small animals have been invaluable in furthering modern understanding of 1 
disease by providing an opportunity to conduct research cheaply, rapidly and with a 2 
degree of complexity not offered by in vitro experiments or other species, in some 3 
situations the information that can be provided by large animals is required to answer 4 
specific research questions(Moran et al., 2016; Ziegler, Gonzalez and Blikslager, 5 
2016). Large animal models offer advantages over small animal models in many 6 
areas.  They are more similar physiologically and anatomically to man (size, tissue 7 
structure and life span) and large animals are an ‘out bred’ population that more 8 
closely represents the heterogeneity of the human population than the ‘inbred’ small 9 
animal strains used in research (Salvatore et al., 2008). Large animals are 10 
phylogenetically closer to humans than rodents and therefore, at a molecular level, 11 
they have greater sequence homology with humans making interpretation of 12 
molecular events in large animals more relevant to man (Henze and Urban, 2010). 13 
Practically, the consequence of working with a large animal means that more body 14 
fluids and cells can be collected with which to perform experiments.   15 
To illustrate how using large animals have facilitated the process of moving MSC 16 
from ‘bench to bedside’ two examples will be considered in this review  – the 17 
treatment of myocardial infarction (MI) and osteoarthritis (OA). The former 18 
represents an example of one single large animal model being considered the ‘gold 19 
standard’ for research, while the latter is an example of the complexities of using 20 








Large animals models for treating myocardial disease using MSC  2 
 3 
There has been a recent increase in the incidence of MI worldwide (Rumana et al., 4 
2008). This is due to many factors such as; an aging population, more sedentary 5 
lifestyles and generally poorer diets (Mohseni et al., 2017). MI is diagnosed as a 6 
cessation of correct blood flow to the heart, leading, in clinical practice, to sudden 7 
death, or ischaemia and subsequent loss of cardiomyocytes (Chiong et al., 2011; 8 
Reddy, 2015). The chances of surviving one MI is high, but post MI complications 9 
are of clinical significance (Chiong et al., 2011).  Localised myocardium loss leads to 10 
heart wall thinning and ventricle dysfunction (Lu et al., 2015). In order to maintain 11 
heart function, the left ventricle dilates to maintain stroke volume and cardiac output 12 
(Mohseni et al., 2017). However, left ventricular dilatation leads to heart failure and 13 
eventual death and MI clearly represents a key pathology that requires therapy 14 
(Reddy, 2015). Over the past 40 years our understanding of MI has increased and, 15 
with this, so have the number of MI related publications (Saleh and Ambrose, 2018). 16 
The possibility of using MSC to regenerate cardiomyocytes became possible when it 17 
was demonstrated in vitro that, in addition to the well-recognised differentiation 18 
products of MSC (into osteoblasts, adipocytes and chondrocytes), MSC can be 19 
differentiated into cardiac cell types (White et al., 2016; Szaraz et al., 2017; Guo et 20 
al., 2018). For example, Szaraz et al. (2017) differentiated human umbilical MSC into 21 
‘cardiac like cells’ that expressed cardiac myocyte differentiation markers such as 22 
myocyte enhanced factor 2C, Cardiac Troponin T, heavy chain cardiac myosin, 23 
signal regulatory protein α and connexion 43. Similarly, Markmee et al. (2017) 24 
showed that after 21 days in cardiogenic culture medium, MSC displayed the 25 
cardiomyocyte markers GATA binding protein 4, cardiac muscle troponin, connexin 26 
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43 and Nkx2.5. Cross-talk between MSC and cardiomyocytes was demonstrated by 1 
Gao, Wang and Borg (2016) who showed that co-culture of MSC with neonatal rat 2 
ventricular myocytes lead to the development of partial electrical properties similar to 3 
the cardiomyocytes (Gao, Wang and Borg, 2016).  4 
In addition to the ability of MSC to differentiate into ‘cardiac like cells’, it has also 5 
been shown that MSC can support cardiac cell viability via secreted factors.  Ismail 6 
et al., (2014) created a model of hydrogen peroxide induced cardiomyocyte injury 7 
and showed that neonatal cardiomyocytes and the cardiac myoblast cell line H9c2 8 
both had significantly increased viability and reduced apoptosis in the presence of  9 
MSC secreted SC1 (Ismail, O’Brien and Barry, 2014). Xing et al., (2009) also 10 
showed that the application of MSC conditioned media to neonatal rat 11 
cardiomyocytes and reduced cardiomyocyte apoptosis via effects on the 12 
mitochondrial pathway (Xiang et al., 2009).  13 
Following these encouraging in vitro results, subsequent small animal studies 14 
showed that MSC had therapeutic efficacy in a MI model. Functionally, MSC were 15 
shown to have a number of positive effects including improving left ventricle function, 16 
increasing vascular density, decreasing scar size (López et al., 2013; Wang et al., 17 
2018) left ventricle stroke volumes and ejection fractions (Dai et al., 2005) and 18 
increasing remodelling of gap junctions (Dai et al., 2005; López et al., 2013; Wang et 19 
al., 2018). There is also some evidence that MSC differentiate, in situ, into cardiac 20 
cells at sites of damage (Nagaya et al., 2005).  21 
However, whilst small animal studies have been useful to show proof of concept for 22 
the use of MSC to treat MI, it has been necessary to use large animal models, 23 
specifically the porcine ischaemic MI model, to confirm the suitability of this cell 24 
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therapy in man. Small animal cardiac parameters such as heart rate, coronary 1 
architecture and capillary density (Harding, Roberts and Mirochnitchenko, 2013) are 2 
markedly different to man, whereas large animal hearts are more similar (Harding, 3 
Roberts and Mirochnitchenko, 2013). The porcine model is the most used for MI 4 
research due to the similarities in heart size and coronary anatomy between pigs and 5 
humans (Swindle et al., 2012). Also, again on a practical note, the relatively high 6 
sequence homology between porcine and human proteins more readily facilitates 7 
research enabling commercially purchased reagents to be used (Dreher, Kamburov 8 
and Herwig, 2011).   9 
The ‘gold standard’ model of porcine MI that is used in all published papers is the 10 
artery occlusion model, in which, a dilation catheter is inflated in the coronary artery.  11 
This catheter blocks blood flow to part of the heart causing infarction development. 12 
However, the remainder of the heart will continue to receive normal blood perfusion 13 
and thus provides a defined border zone between normal and damaged tissue for 14 
comparative evaluation (McCall et al., 2012).  Schuleri et. al. 2009 showed a positive 15 
effect of using autologous BM-MSC, administered 12 weeks post infarct to treat MI. 16 
Magnet resonance Imaging (MRI) was used to assess infarct size, myocardial blood 17 
flow and left ventricle function. In this study an apparent dose dependent effect of 18 
MSC administration on infarct size was observed.  19 
Whilst Schuleri et al (2009) used autologous MSC in their experimental work, there is 20 
much interest in allogeneic MSC therapy. Allogeneic MSC offer significant 21 
advantages over autologous MSC including their ease of use, reduced cost and 22 
absence of donor site complications (Schuleri et al., 2009). Quevedo et. al.(2009) 23 
showed that allogeneic MSC are able to regenerate an experimentally created, 24 
chronically infarcted myocardium via long term engraftment (Quevedo et al., 2009). 25 
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Following MRI, cell fate was confirmed using Y chromosome cell tracking. In 1 
comparison to the control group, infarct size reduced by 5.4%, ejection fraction 2 
increased by 6.3% and levels of MSC engraftment correlated with functional 3 
recovery levels (measured by assessing contractility and myocardial blood flow). In 4 
this study, the implanted MSC were only detected within the infarct area or the infarct 5 
border with 14% showing evidence of myocyte commitment (assessed by the 6 
presence of cardiac transcription factors GATA-4 and Nkx2.5 or structural cardiac 7 
proteins α-sarcomeric actin and tropomyosin) (Quevedo et al., 2009). Similarly 8 
William et. al. (2013) also investigated the use of allogeneic MSC with excellent 9 
results - an 19.62% reduction in scar size after 12 weeks, progressing to 28.09% 10 
after 24 weeks and a functional improvement in heart function (Williams et al., 2013). 11 
The studies reported above all showed positive effect of administrating MSC as early 12 
as 12w post infarct creation.  However, administration at earlier time points has also 13 
been shown to be efficacious, for example, administration at 3 days post-infarct 14 
(Hatzistergos et al., 2010), suggesting that the optimal time window for therapeutic 15 
intervention is not fully established. Lee et al., showed that administering EVs after 16 
30 minutes post infarct had no effect, thusw ork continues in the porcine model to 17 
determine these important criteria. Examples of these studies are summarised in 18 










Cell source  
Cell number 






and date  
BM-
MSC 







blood flow  
Schuleri et 
al., 2009 














A-MSC Autologous  2 30 minutes  







the defect   
Lee et al., 
2015 











Autologous  No examples were found in the literature  




8 weeks  
Improved left 
ventricle 
infarct area but 










Table 1 shows examples of the different cell types used and when they were administered in large 1 
animal models using MSC as a therapeutic for myocardial infarction. BM-MSC – Bone marrow 2 
Mesenchymal Stem Cells, A-MSC – Adipose Mesenchymal Stem Cells, UC-MSC – Umbilical Cord 3 
Mesenchymal Stem Cells.   4 
 5 
Due to positive results in the porcine MI model, MSC are now being used in clinical 6 
trials to treat a variety of cardiac diseases in man (Table 2).  In these clinical trials to 7 
date, all have reported that the use of MSC is safe and a significant majority of 8 
studies have reported a positive outcome despite a high number of variables in the 9 
studies. However, it should be noted that many knowledge gaps still exist and study 10 
designs should now attempt to gain knowledge, such as the optimum dosage, cell 11 





















Author and Date Type of heart 
disease  
MSC type / 
source 
Number of cells 
administered 
x106 Study type Outcome 
Ascheim et al., 
2014 ICM or NICM BM, allogeneic 
25  
Phase 2 Safe and positive  
Bartolucci et al., 
2017 ICM or NICM US, allogeneic  
1/kg of body 
weight  Phase 1/2 Safe and positive  
Bartunek et al., 
2013 ICM BM, autologous  
6-12 after 
treatment with 
cardiac cocktail Phase 2/3 Safe and positive  
Bartunek et al., 
2017 ICM BM, autologous 
24 
Phase 3 Safe and positive  
Butler et al., 
2017 NICM BM, allogeneic 
1.5/kg body 
weight  Phase 2 Safe and positive  
Chen et al., 2004 AMI BM, autologous 50 to 60 Phase 2 Safe and positive  
Chen et al., 2006 ICM BM, autologous >5 Phase 1/2 Safe and positive  
Florea et al., 
2017 ICM BM, allogeneic 
20 or 100  
Phase 2  Safe and positive  
Gao et al., 2015 AMI UC, allogeneic  6 Phase 2 Safe and positive  
Guijarro et al., 
2016 ICM BM, autologous 
61 
Phase 1 Safe 
Hare et al., 2009 AMI BM, allogeneic 0.5, 1.6 and 5/kg Phase 1 Safe 
Hare et al., 2012 ICM 
BM, allogeneic 
and autologous 
20, 100 or 200 
Phase 1/2 Safe and positive  
Hare et al., 2017  DCM BM, autologous 20, 100 or 200 Phase 1/2 Safe and positive  
Henry et al., 
2017 ICM ABM, autologous  
40 and 80 
Phase 2  Safe and positive  
Houtgraaf et al., 
2012  AMI ABM, autologous 
20  
Phase 1/2 Safe and positive  
Karantalis et al., 
2014 ICM BM, autologous 
8-20 
Phase 2/3 Safe and positive  
Kastrup et al., 
2017 ICM ABM, allogeneic 
110 
Phase 1 Safe 
Mathiasen et al., 
2015 ICM BM, autologous 
77.5  
Phase 1/2 Safe and positive  
Mohamadnejad 
et al., 2007 ICM BM, autologous 
32 
Phase 1 Safe 
Musialek et al., 
2015 AMI UC, allogeneic 
30 
Phase 1  Safe 
Qayyum et al., 
2017 ICM ABM, autologous 
70 
Phase 2  Safe and positive  
Rodrigo et al., 
2013 AMI BM, autologous 
10 
Phase 1 Safe 
 1 
Table 2 Published clinical trials that use defined numbers of mesenchymal stem cells (MSC) for 2 
treating heart disease. This table shows the type of heart disease treated, the source of the MSC, the 3 
cell number and the study outcomes. Ischemic Cardiomyopathy, NICM- Non-ischemic 4 
Cardiomyopathy, AMI – Acute myocardial infarction, DCM – dilated cardiomyopathy. BM – bone 5 
marrow derived MSC, UC – umbilical cord derived MSC, ABM – adipose derived MSC. 6 
11 
 
Large animal models for osteoarthritis  1 
 2 
In contrast to the single porcine large animal model that has been used to show the 3 
efficacy of MSC in the treatment of MI, a variety of large animal models have been 4 
used to demonstrate the therapeutic benefits of MSC in the treatment of 5 
Osteoarthritis (OA) prior to clinical trials.  6 
OA is the gradual degeneration of articular cartilage within synovial joints (Sharma et 7 
al., 2013). It is estimated that, worldwide, eight million people over the age of 65 8 
suffer with this disease (Neogi, 2013). OA is the result of structural and functional 9 
failures within the synovial joint (Nuki, 1999). This is due to the pathological loss of 10 
articular cartilage coupled with sub-chondral bone thickening, osteophyte 11 
development, ligament degeneration and varying levels of inflammation(Chen et al., 12 
2017). These pathologies all contribute to pain induced joint morbidity (Chen et al., 13 
2017). OA can be classified into primary and secondary forms based on aetiology.  14 
Primary forms of the disease are age-related, whilst trauma is the most common 15 
form of secondary OA (Samson et al., 2007).  16 
There are currently no disease-modifying therapeutics licensed for use in OA and 17 
there is a huge clinical need for effective therapies. In recent years, MSC have been 18 
used to treat OA in pre-clinical and clinical studies. The rationale behind the use of 19 
MSC to treat OA was initially proposed to be harnessing the potential of MSC to 20 
differentiated into mesodermal tissues including cartilage. It was proposed that MSC, 21 
injected into damaged joints, differentiate into the tissues of the joints and healed the 22 
lesions. However, more mature understanding of the mechanism of action of MSC 23 
suggest that rather than acting as building blocks, they are acting in a paracrine 24 
fashion to modulate cellular responses (Kong et al., 2017). 25 
12 
 
As outlined for MI research above, the pathway to human clinical trials for using 1 
MSC as an OA therapeutic is based on in vitro, small animal and then large animal 2 
models.   3 
Evidence that MSC have a beneficial effect on the native cells within the joint has 4 
been shown in numerous studies (reviewed by (Li et al., 2019). For example, the co-5 
culture of chondrocytes and MSC has been shown to increase glycosaminoglycan 6 
synthetic activity as well as increased expression of chondrogenesis-related genes 7 
(type II collagen and SOX-9) whilst simultaneously downregulating the expression of 8 
osteogenic markers and chondrocyte hypertrophic markers (Bian et al., 2011; Huang 9 
et al., 2018; Kim et al., 2018).  Similarly, It has been shown that MSC can promote 10 
both macroscopic and microscopic healing of meniscal defects, usually in the 11 
presence of biocompatible scaffolds (Pabbruwe et al., 2010; Zellner et al., 2010; 12 
Mandal et al., 2011; Nerurkar et al., 2011). 13 
In small animals MSC have been shown to have disease modifying properties in a 14 
number of experimental small OA models, such as in mouse and rabbit anterior 15 
cruciate ligament transection models (Chiang et al., 2016). Similarly, Tang et al., 16 
(2017) also showed that MSC decreased osteophyte and fibrous tissue formation 17 
and increased type II collagen and aggrecan in a rat medial menisectomy model 18 
after the administration of MSC (Tang et al., 2017). Improved cartilage repair has 19 
also been shown in chemically induced murine arthritis models  and in focal cartilage 20 
defect models (Kehoe et al., 2014; Mak et al., 2016). 21 
Whilst MSC have been used in small animal OA models as described above, large 22 
animals offer significant advantages over small animals for the assessment of the 23 
therapeutic benefits of MSC prior to clinical trials.  Large animals have similar bone 24 
13 
 
development to man compared to small animals i.e. they have closed growth plates 1 
at skeletal maturity and large animal models of OA occur more slowly than in small 2 
animal models, mimicking the natural disease in man (McGovern, Griffin and 3 
Hutmacher, 2018). However, it must be noted that whilst all large animals will 4 
develop OA naturally as they age, there are no models of spontaneous early onset 5 
OA as there are in small animals (Bendele, White and Hulman, 1989; Jimenez et al., 6 
1997; Poole et al., 2010).   7 
Unlike the use of a single ‘gold standard’ large animal model for evaluating the 8 
effects of MSC in MI, many models exist for the generation of OA in large animals. 9 
Experimental models of large animal OA are primarily surgically induced damage, 10 
although there are two reports of the use of MSC to treat chemically induced arthritis. 11 
Mokbel et al (2011) used amphotericin-B in a donkey OA induction model and 12 
demonstrated that the injected cells had integrated within the existing cartilage and 13 
the reparative effects of the MSC were observed both clinically and radiographically 14 
(Mokbel et al., 2011). Barrachina et al (2018) described the use of bone marrow 15 
MSC to treat amphotericin-B induced arthritis in an equine radio-carpal joint.  In this 16 
study the application of MSC decreased synovial inflammation, enhanced the gross 17 
appearance of the cartilage and delayed proteoglycan loss in comparison to the 18 
control. This study also reported differences in outcome between naïve MSC and 19 
MSC primed with tumour necrosis factor – alpha (TNFα) and interferon-gamma (IFN-20 
). This data is particularly useful in considering the clinical translation of MSC as 21 
there is ongoing discussion as to the need for MSC priming/conditioning prior to use 22 
(Succar et al., 2016; Barrachina et al., 2018) 23 
Whilst there are only currently two reported studies on the use of MSC to treat 24 
chemically induced arthritis in large animal models, many studies have reported the 25 
14 
 
use of different MSC to treat surgically induced arthritis as a proxy for the human 1 
disease. (Table 3). In these studies a wide range of large animal species and 2 
different surgical techniques have been used to model OA. These techniques include 3 
anterior cruciate ligament transection (ACLT), meniscectomy and medial meniscal 4 
transection and osteochondral fragment defect models. These are all well 5 
standardised procedures, with each model posing its own advantages and 6 
disadvantages (reviewed in (Kuyinu et al., 2016).  7 
Whilst many studies use autologous cells, as discussed previously in the treatment 8 
of MI, the use of allogeneic MSC to treat OA is of considerable interest. For example, 9 
human BM-MSC were used to treat ACLT induced OA in a porcine model 16 weeks 10 
post-surgery (Tseng et al., 2018). At 5 months post implantation, there was a 11 
significant difference between the regeneration of new tissue, with the treated group 12 
showing evidence of cartilage-like tissue. Similarly, Hatsushika et. al.(2014) 13 
investigated the effect of allogeneic synovial MSC following partial meniscectomy in 14 
a porcine model and showed increased meniscus regeneration and prevention of OA 15 
progression by week 16 post-surgery (Hatsushika et al., 2014). Murphy et al (2003) 16 
has also shown that the administration of allogeneic bone marrow MSC following 17 
ACTL in goats led to significantly increased tissue regeneration including the 18 
meniscus and decreased articular cartilage degeneration, osteophyte remodelling 19 
and subchondral sclerosis in comparison to the hyaluronan control(Murphy et al., 20 
2003).  These studies are important for the potential clinical applications of MSC as 21 
they may suggest there is no requirement for donor matching when using MSC 22 
therapeutically.  23 
Whilst the studies above and those reported and summarised in table 3 shows that 24 
MSC had a positive effect in a number of different models of OA, large animal 25 
15 
 
studies have shown that MSC therapies are not always successful. Evaluation of the 1 
effects of allogeneic MSC on the development of OA following complete 2 
meniscectomy in a sheep model has been reported (Song et al., 2014; Delling et al., 3 
2015). After 12 weeks, MRI, radiography and post-mortem evaluation showed no 4 
significant difference in the degree of OA between the treatment group and the 5 
control. Similarly, the use of MSC in the osteochondral fragment model of OA 6 
induction in horses showed no significant effects (Frisbie et al., 2009). This reporting 7 
of negative results from a large animal model is important data, inducing caution in 8 
the use of these cells. MSC therapy has widely been touted as a miraculous ‘cure 9 
all’, particularly in the popular press and amongst less scrupulous clinicians, and 10 
stringent efforts must continue to be made to ensure tight but feasible regulation of 11 
these therapies to ensure patient safety, as the use of MSC to treat patients is well 12 
underway (Table 4) (Bianco et al., 2013). A number of controlled clinical trials have 13 
been reported, with good outcomes in both visual analogue scale for chronic pain 14 
and  western Ontario and McMaster Universities arthritis index scores (measures of 15 
joint morbidity), as well as range of movement, , improved pain and joint motility 16 
scores following treatment (Lamo-Espinosa et al., 2016; Pers et al., 2016).  These 17 
studies demonstrate the translation of MSC therapy into man whilst large animal 18 







Animal Cell type  Method of OA 
induction 





Sheep BM-MSC ACLT + medial 
meniscectomy 
Autologous  Meniscal and 
cartilage repair 
10 Song et 
al., 2014  
A-MSC ACLT + medial 
meniscectomy 
Autologous  Cartilage repair  20 million Ude et 
al., 2014 
UC- MSC ACLT  Allogeneic  Cartilage repair 50 Million  Wang et 
al., 2009  
S-MSC No examples were found in the literature  
Goat BM-MSC ACLT Autologous Cartilage repair 10 million Murphy 
et al., 
2003 
A- MSC No examples were found in the literature  
UC-MSC No examples were found in the literature  
S-MSC No examples were found in the literature 





Allogeneic No significant 




10 million Xia et al., 
2018 
UC- MSC No examples were found in the literature  
  
S-MSC No examples were found in the literature  
17 
 
Horse  BM-MSC Osteochondral 
fragmentation 






al., 2009 A- MSC 
UC-MSC No examples were found in the literature  
S-MSC No examples were found in the literature  
Donkey BM-MSC Partial thickness cartilage defect  
A- MSC Full thickness 
Cartilage 
defect 
Autologous  Clinical and 
radiographic 
improvement 
2 million  Mokbel 
et al., 
2011 
UC-MSC No examples were found in the literature  
S-MSC No examples were found in the literature 
Dog  BM-MSC Full thickness 
cartilage 
defect  










10 million li et al., 
2018 
 









5 million Miki et 





Allogeneic  Cartilage repair 15 million Park et 
al., 2013 
S-MSC No examples were found in the literature 
 1 
Table 3 Examples of large animal models used to study the efficacy of bone marrow (BM), adipose 2 
(A), umbilical cord (UC) and synovial (S) derived MSC in the treatment of experimentally induced 3 
18 
 
osteoarthritis (OA). ACLT – Anterior Cruciate  Ligament Transection. MSC – Mesenchymal Stem Cells. 1 
OA- Osteoarthritis.  2 
 3 
Author and Date 
Mode of 
delivery 
MSC type & 
Source  Phase  Outcome  





Marrow  1 Safe and Positive 





Marrow  1/2  Safe and Positive 





Marrow  1 Safe  






stem cells from 
bone marrow  
1 Safe   





Marrow   2 Safe and Positive 






Marrow  1/2 Safe and Positive 





cord  1/2 Safe and Positive 




Marrow  2 Safe and Positive  














Marrow  2/3 Safe and Positive 




derived  1/2 Safe and Positive 









Marrow  1 Safe  
Table 4 lists the published clinical trials that use mesenchymal stem cells (MSC) for treating 4 
osteoarthritis (OA), the method of administration, the source of the MSC and the study 5 





Large animal models have been widely used to facilitate the translation of MSC from 2 
the laboratory to patient. The aim of this review is to illustrate how MSC have been 3 
translated to man through large animal models.  For this, two very different examples 4 
have been used – MI (where one gold standard large animal model has been used in 5 
one species to show efficacy) and OA (where multiple species and models have 6 
been used).  It is clear that using multiple models and different experimental 7 
approaches makes interpretation of results difficult and the use of a single large 8 
animal model is preferable. It is also clear that the majority of publications only report 9 
positive outcomes of MSC therapy and that encouragement of the publication of 10 
negative outcomes should be made as this will allow a more accurate assessment of 11 
therapeutic efficiency.  However, used appropriately, large animal models allow 12 
clinically relevant assessments of safety, efficacy and dosing prior to clinical trials 13 
and continue to provide a research platform that can be used to evaluate the value of 14 
cell based therapies. 15 
 16 
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